Fortis may be out of F&O if results delayed

The National Stock Exchange of India on Thursday said it will exclude Fortis Healthcare from the derivatives segment if the company fails to submit its financial results for the September and December quarter by March 1, reports Our Bureau.

So far, Fortis Healthcare has failed to submit its quarterly financial results for the September and December quarter, said NSE. Fortis has intimated to exchanges that its board will consider results for the two quarters in meeting on February 28.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    Karnataka State Information Commission slaps ₹1 lakh penalty on BDA official for failing to provide information

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    NSQ reporting nearly doubles in 2025, buoyed by greater state participation

    Two Gyms In Firozabad Raided, Seize 20 Mephentermine Injections Amid Health Concerns

    Two Gyms In Firozabad Raided, Seize 20 Mephentermine Injections Amid Health Concerns

    Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh

    Delhi Drugs Control Department Seizes Insulin Stock Worth Rs 20.06 Lakh

    Kerala Health Department Has Launched The MeHEALTH App

    Kerala Health Department Has Launched The MeHEALTH App

    War Could Affect Up To ₹5,000 Crore Of Pharma Exports And Disrupt Supply Chains

    War Could Affect Up To ₹5,000 Crore Of Pharma Exports And Disrupt Supply Chains